Introduction
============

Cytoskeleton-associated protein 2-like (*CKAP2L*) gene is composed of 9 exons and encodes a protein that is considered to be indispensable to neural stem or progenitor cell division.[@b1-ott-12-1171] This protein has been described as Radmis (radial fiber and mitotic spindle protein) based on its location to the radial fiber and mitotic spindle in neural stem/progenitor cells (NSPCs).[@b1-ott-12-1171] Moreover, CKAP2L has been demonstrated to be a component of human centrosome, and is situated in the spindle, the midbody, and spindle pole.[@b2-ott-12-1171] Current studies provide evidences proving that loss-of-function mutations in CKAP2L is one of the main cause of Filippi syndrome.[@b3-ott-12-1171] A tight regulation of CKAP2L expression is very crucial for appropriate mitosis of neural precursor cells since overexpression of this protein leads to dramatic increase in cell mitosis.[@b3-ott-12-1171] So far, the expression and function of CKAP2L in other tissues and in cancer progression are unknown.

Lung cancer is a leading cause of cancer-related death worldwide, as lung adenocar-cinoma (LAD) is the most common histological type of it.[@b4-ott-12-1171]--[@b7-ott-12-1171] Although much progress has been made in LAD therapy, its prognosis still remains poor.[@b8-ott-12-1171] Furthermore, although advances in molecular-targeted therapy have improved treatment in patients with molecular mutations, it eventually fails owing to drug resistance.[@b9-ott-12-1171],[@b10-ott-12-1171] Hence, a deeper understanding of the molecular mechanism of LAD and efforts toward prophylaxis and early diagnosis will help in treating this disease.

Here, we analyzed the expression of *CKAP2L* in LAD tissues and the prognostic value of this gene in LAD. The function of CKAP2L in LAD cell proliferation and motility was investigated by constructing H460 and A549 cells with silenced *CKAP2L*. Finally, we quested the potential mechanism of how *CKAP2L* affects LAD cell proliferation and motility. Our data manifested that *CKAP2L* might be a facilitator in the development of LAD and could be used as a candidate predictor in LAD patients.

Methods
=======

Data collection and patients
----------------------------

The mRNA expression data of 535 LAD tissues and 59 normal lung tissues were collected from The Cancer Genome Atlas (TCGA, <https://tcga-data.nci.Nih.gov/tcga>). In addition, 52 LAD cases resected at the First Affiliated Hospital of Kunming Medical University from 2008 to 2012 were gathered and analyzed in this paper. Informed consent was obtained from these 52 LAD patients. All the patients received no preoperative radiotherapy and/or chemotherapy. The clinical--pathological characteristics of these 52 samples are shown in [Table 1](#t1-ott-12-1171){ref-type="table"}.

Cell culture
------------

Human LAD cell lines H460, A549, SPC-A1, and normal lung epithelial cell line BEAS-2B were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). H460 cells, SPC-A1 cells, and A549 cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium and incubated at 37°C with 5% CO~2~. BEAS-2B cells were cultivated in DMEM/F12. FBS (10%), penicillin (100 U/mL), and streptomycin (100 mg/mL) were contained in the culture media.

Quantitative reverse transcription PCR (qRT-PCR)
------------------------------------------------

Total RNA was extracted from the 52 LAD samples and the corresponding paracancer tissues as well as H460, A549, SPC-A1, and BEAS-2B cell lines using RNAiso Plus (TaKaRa Biotechnology, Dalian, China). Then cDNA were synthesized using a HiFiScript cDNA Synthesis Kit (CwBio, Beijing, China) with the extracted RNA as template. Afterwards, we utilized Applied Biosystems 7300 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) to determine the mRNA expression level of *CKAP2L*. The primers used for qPCR were: CKAP2LF-5′-CAGGAGTACCTTGCAGCCAA-3′, CKAP2LR:5′-TGCTGATGGACAGATTTAGAAGGT-3′; GAPDHF: 5′-GGAGCGAGATCCCTCCAAAAT-3′, GAPDHR: 5′-GGCTGTTGTCATACTTCTCATGG-3′, where GAPDH was applied for normalization. Relative expression of *CKAP2L* was computed utilizing the 2^-ΔΔCT^ method.[@b11-ott-12-1171]

Transfection
------------

*CKAP2L* siRNA1 (si-CKAP2L1: 5′-AAACUGUCACUG AAGAGUC-3′), *CKAP2L* siRNA2 (si-CKAP2L2: 5′-ACUGU CACUGAAGAGUCAU-3′), and scrambled siRNA (si-con: 5′-GAAGUCACUGUCAAACUAG-3′) were synthesized by GENEWIZ Co., Ltd. (Suzhou, China). The siRNA was transfected into LAD cells utilizing Lipofectamine 2000 (Invitrogen, Shanghai, China). Afterwards, the cells were kept at 37°C for 6 hours followed by replacement of the media with fresh medium. After 48 hours of cultivation, cells were used to carry out the following tests.

Cell counting kit-8 (CCK8) test
-------------------------------

After being transfected with si-CKAP2L or si-con, A549 and H460 cells were inoculated into a 96-well plate and cultured under standard conditions. The proliferation of these cells was determined using CCK8 at 24-, 48-, 72-, and 96-hour time points following the manufacturer instructions. The proliferation curves were plotted using GraphPad Prism 5.0.

Colony formation assay
----------------------

Single cell suspensions of A549 and H460 cells with depleted *CKAP2L* were prepared and plated into 12-well plates (500 cells/well) with RPMI-1640 medium. After being conventionally cultured for 2 weeks, the cells were fixed with 4% paraformaldehyde and stained by 0.1% crystal violet dye. Finally, we counted the number of clones under light microscopy with 2× magnification.

Wound healing assay
-------------------

A549 and H460 cells with depleted *CKAP2L* were plated on a 6-well plate and grown to confluence. Then, we made a horizontal wound using a 200-µL pipette tip after the cells had been starved for 24 hours. After that, we captured the wounds and measured their width under an optical microscope (Olympus, Tokyo, Japan) after 0 hour and 24 hours scratching. The assays were carried out for at least three times.

Transwell invasion and migration assays
---------------------------------------

The invasive and migration ability of A549 and H460 cells with silenced *CKAP2L* were analyzed utilizing Transwell assays. For invasion tests, the cells were seeded into the upper chambers, which were pre-coated with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) and then went into a 24 hours cultivation. Afterwards, we fixed the invasive cells with 4% paraformaldehyde and stained them using 0.1% crystal violet dye. The invasive cells were photographed in five random fields and counted under a light microscope with 200× magnification. The procedure of tranwell migration assay was similar to invasion assays. However, the upper chambers were not coated with Matrigel. All the experiments were performed in triplicate.

Western blot
------------

We extracted total protein from A549 cells after silencing *CKAP2L* and performed SDS-PAGE to separate the proteins. The proteins were then electrotransferred to the polyvinyli-dene fluoride membranes (Millipore, Bedford, MA, USA) and blocked by 5% nonfat milk. Afterwards, the membranes were incubated with the primary anti-bodies (ERK, p-ERK, MEK, p-MEK, and GAPDH) and secondary anti-bodies successively. The expression of GAPDH was used as internal reference. Finally, the protein bands were detected using an enhanced chemiluminescence plus detection kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA). All the experiments were performed three times.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS 15.0 software (IBM, Chicago, IL, USA) and the values were shown as mean ± SD. Student's *t*-test was carried out to compare the difference between two groups. One-way ANOVA was utilized to compare the difference between multiple groups. Both the samples obtained from TCGA database and collected by ourselves were plotted into high *CKAP2L* expression and low *CKAP2L* expression groups on the basis of the median of *CKAP2L* mRNA expression. Kaplan--Meier analysis was used to analyze the relationship between *CKAP2L* expression and overall survival with log-rank test applied for comparison. Pearson's chi-squared (*χ*^2^) test was performed to determine the association between *CKAP2L* expression and clinical--pathological factors. Cox proportional hazards model was performed to identify independent prognostic predictors. It was considered as significant when *P*\<0.05.

Results
=======

*CKAP2L* is overexpressed in LAD and is predictive of poor prognosis
--------------------------------------------------------------------

On the basis of the data taken from the TCGA database, we identified that the mRNA expression level of *CKAP2L* was dramatically higher in LAD tissues (n=535) than that in normal lung tissues (n=59) ([Figure 1A](#f1-ott-12-1171){ref-type="fig"}, *P*\<0.0001). Likely, by analyzing the mRNA expression of CKAP2L in the 52 LAD tissue samples that were collected in The First Affiliated Hospital of Kunming Medical University, we observed higher expression of *CKAP2L* in LAD tissues than in normal paracancer tissues ([Figure 1C](#f1-ott-12-1171){ref-type="fig"}, *P*\<0.0001). By Kaplan--Meier analysis, we discovered that higher *CKAP2L* expression was positively correlated with shorter overall survival both based on the TCGA database ([Figure 1B](#f1-ott-12-1171){ref-type="fig"}, *P*=0.007) and the clinical data collected by ourselves ([Figure 1D](#f1-ott-12-1171){ref-type="fig"}, *P*=0.024).

In correlation analysis ([Table 2](#t2-ott-12-1171){ref-type="table"}), statistically significant association was observed between *CKAP2L* expression and stage (*P*\<0.001), lymph node status (*P*=0.002), or metastasis (*P*=0.025). No significant relationship was found between *CKAP2L* expression and age, gender, and T-stage. For the purpose of examining whether *CKAP2L* can be used as an independent predictor of prognosis in LAD, Cox regression analysis was carried out. By univariate analysis, we found that *CKAP2L* expression (*P*=0.0298), stage (*P*=0.03), T-stage (*P*=0.011), metastasis (*P*=0.005), and lymph node status (*P*=0.001) can be regarded as prognostic factors ([Table 3](#t3-ott-12-1171){ref-type="table"}). Multivariate analysis revealed that metastasis (*P*=0.015) and lymph node status (*P*=0.003) could be used as independent prognostic factors in LAD ([Table 3](#t3-ott-12-1171){ref-type="table"}).

Knockdown of *CKAP2L* suppresses proliferation of LAD cells
-----------------------------------------------------------

By qRT-PCR, we found that the expression of *CKAP2L* is dramatically higher in LAD cell lines H460, A549, and SPC-A1 than that in normal lung cell line BEAS-2B ([Figure 2A](#f2-ott-12-1171){ref-type="fig"}, *P*\<0.01). With the purpose of exploring the effect of *CKAP2L* expression on LAD cell growth, we used RNA interference to reduce the expression of *CKAP2L* gene in LAD cells and constructed LAD cells with silenced CKAP2L. As shown in [Figure 2B--D](#f2-ott-12-1171){ref-type="fig"}, both the mRNA and protein expression levels of CKAP2L were dramatically reduced after transfected with si-CKAP2L 1 or si-CKAP2L 2 compared with the si-NC group. In the following experiments, we selected si-CKAP2L 2 to reduce *CKAP2L* expression in A549 and H460 cells. By CCK8 assays, we observed that depletion of *CKAP2L* remarkably decreased the OD value at 24, 48, and 72 hours in both A549 and H460 cells (*P*\<0.05, [Figure 3A--B](#f3-ott-12-1171){ref-type="fig"}). In colony formation assays, similar results were observed. The numbers of formatted A549 and H460 colonies in si-CKAP2L groups were dramatically less than that in the corresponding si-con groups (*P*\<0.05, [Figure 3C--D](#f3-ott-12-1171){ref-type="fig"}). These results demonstrated that down-regulation of *CKAP2L* exhibited an inhibitory effect on A549 and H460 cell proliferation, implying that *CKAP2L* promoted LAD progression.

Knockdown of *CKAP2L* suppresses migration and invasion of LAD cells
--------------------------------------------------------------------

To investigate whether CKAP2L expression was involved in cell migration and invasion, Transwell and wound healing assays were carried out in A549 and H460 cells transfected with si-CKAP2L or si-con. As we predicted, knockdown of *CKAP2L* dramatically reduced the numbers of migrated and invasive A549 ([Figure 4A](#f4-ott-12-1171){ref-type="fig"}) as well as H460 cells ([Figure 4B](#f4-ott-12-1171){ref-type="fig"}) (*P*\<0.01). Similarly, in wound healing assays, depletion of *CKAP2L* significantly reduced the migration distances of A549 cells ([Figure 5A](#f5-ott-12-1171){ref-type="fig"}) as well as CKAP2L cells ([Figure 5B](#f5-ott-12-1171){ref-type="fig"}). These observations implied that *CKAP2L* was a positive regulator of LAD motility.

Knockdown of *CKAP2L* suppresses mitogen-activated protein kinase (MAPK) signaling pathway
------------------------------------------------------------------------------------------

Afterwards, we explored the effect of knockdown of *CKAP2L* on MAPK signaling pathway in A549 cells by Western blot. Our results showed that the ratio of phospho-MAPK/extracellular signal-regulated kinase (ERK) kinase (MEK)/MEK and p-ERK/ERK were reduced obviously in A549 cells after depleting *CKAP2L* ([Figure 6](#f6-ott-12-1171){ref-type="fig"}, *P*\<0.01). This observation suggested that CKAP2L might act as a positive regulator in LAD progression by regulating MAPK signaling pathway.

Discussion
==========

Out of control mitosis is a distinguishing characteristic of tumor cells, and this feature is effectively used to treat cancer by utilizing anti-tubulin drugs.[@b12-ott-12-1171] However, high-grade LAD is often highly chemo-sensitive and these treatment is usually failed due to drug resistance. Therefore, it is of great significance to get insightful understanding into the mechanism of LAD progression and develop effective prophylaxis and early diagnosis methods. CKAP2L, also called radmis, is a microtubule-associated protein that appears at the mitotic-phase via the post-translational regulation and takes vital part in neural progenitor cell division.[@b1-ott-12-1171] Down-regulation of this gene triggered the multipolar spindles and chromosome segregation in neural stem/progenitor cells (NSPCs).[@b1-ott-12-1171]

To date, little is known about the function of CKAP2L in cancer development. CKAP2 is an important paralog of CKAP2L. Previous reports have demonstrated that CKAP2 is up-regulated in primary human gastric adenocarcinomas. In breast cancer, CKAP2 was suggested to be an independent prognostic marker.[@b13-ott-12-1171] In addition, the overexpression and oncogenic nature of CKAP2 has also been illustrated in prostate cancer,[@b14-ott-12-1171] ovarian cancer,[@b15-ott-12-1171] and glioma.[@b16-ott-12-1171] Therefore, we supposed that CKAP2L might also participate in the occurrence and development of lung cancer.

In our present study, we identified that *CKAP2L* was overexpressed in LAD tissues ([Figure 1A and C](#f1-ott-12-1171){ref-type="fig"}), and this overexpression is closely associated with poor prognosis of LAD patients ([Figure 1B and D](#f1-ott-12-1171){ref-type="fig"}). Chi-squared test revealed that higher *CKAP2L* expression seems to be positively correlated with higher stage, lymph node status, and metastasis. Univariate analysis showed that stage, T-stage, metastasis and lymph node status, and *CKAP2L* expression could serve as prognostic factors for LAD. However, the result of multivariate analysis found that only metastasis (*P*=0.015) and lymph node status (*P*=0.003) could be considered as independent prognostic factors for overall survival although we observed a trend toward a correlation between high *CKAP2L* expression and poor outcomes (*P*=0.430). A larger sample size is needed to verify our current analysis results. The expression changes and prognostic value of *CKAP2L* implied that it probably plays an important promotional part in the occurrence and progression of LAD.

We then explored the influence of silencing *CKAP2L* on LAD cell proliferation and motility. The results showed that knockdown of *CKAP2L* dramatically impaired A549 and H460 cell proliferation, migration, and invasion abilities in vitro, indicating that CKAP2L functioned as a facilitator in LAD progression. In the migration and invasion assays, we observed that the H460 cells were more susceptible to

*CKAP2L* silencing than A549 cells. This difference might be attributed to the discrimination between these two cell lines. H460 cells were isolated from pleural effusion of a patient with lung cancer. While A549 cell line was isolated from lung cancer tissues of a male. The expression level of p53 in H460 cells was similar to that in normal cells, and the keratin and vimentin fiber staining result was positive. As a novel mitotic spindle protein, we supposed that CKAP2L might affect LAD cell proliferation by participating in polymerization/ stabilization of microtubules and then regulating cell mitosis.[@b1-ott-12-1171] MAPK signaling pathway has been demonstrated to take part in diverse fundamental cellular processes, such as cell proliferation, migration, division, and death.[@b17-ott-12-1171]--[@b19-ott-12-1171] Moreover, the involvement of this pathway in proliferation has been reported in various cancer types,[@b20-ott-12-1171]--[@b22-ott-12-1171] including LAD.[@b23-ott-12-1171] Since silencing *CKAP2L* exhibits similar inhibitory effect on H460 and A549 cell proliferation and motility, we only explored the effect of knockdown *CKAP2L* on MAPK signaling pathway in A549 cells. We observed that knockdown of CKAP2L dramatically reduced the ratio of p-MEK/MEK and p-ERK/ERK (*P*\<0.01). This data suggested that CKAP2L might promote cell proliferation partially by regulating MAPK signaling pathway. However, further investigation is needed to find out how CKAP2L talks with the MAPK signaling pathway.

Conclusion
==========

Our results strongly suggested that CKAP2L plays an important facilitating role in the development of LAD and is predictive of poor prognosis of LAD patients. In the future studies, we will carry out the experiments in animal models and attempt to clarify the possible mechanisms that underlie CKAP2L involvement in LAD proliferation and migration.
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![Enhancement of *CKAP2L* mRNA expression in LAD was associated with poor prognosis.\
**Notes:** (**A**) Statistical analysis of *CKAP2L* mRNA expression in LAD samples (n=535) and normal lung samples (n=59) using the data taken from TCGA database. (**B**) The association between *CKAP2L* expression and overall survival time of LAD patients based on the TCGA database. The samples were divided into high CKAP2L expression (n=261) and low *CKAP2L* expression (n=261) groups according to the median of *CKAP2L* expression. (**C**) *CKAP2L* mRNA expression in LAD tissues (n=52) and the corresponding paracancer tissues (n=52) detected by qRT-PCR. (**D**) The association between *CKAP2L* expression and overall survival time of LAD patients based on the clinical data we collected from 52 patients. The samples were divided into high *CKAP2L* expression (n=26) and low *CKAP2L* expression (n=26) groups according to the median of *CKAP2L* expression.\
**Abbreviations:** *CKAP2L*, cytoskeleton-associated protein 2-like; LAD, lung adenocarcinoma; TCGA, The Cancer Genome Atlas.](ott-12-1171Fig1){#f1-ott-12-1171}

![*CKAP2L* mRNA and protein expression levels were down-regulated by CKAP2L siRNA in lung adenocarcinoma cells.\
**Notes:** (**A**) CKAP2L mRNA expression was enhanced in H460, A549, and SPCA1 cells compared with that in BEAS-2B cells. (**B**)The mRNA expression level of CKAP2L in A549 cells was dramatically decreased after transfection with si-CKAP2L1 or si-CKAP2L2. (**C**) CKAP2L protein expression level in A549 cells transfected with si-CKAP2L1 or si-CKAP2L2, determined by Western blot. (**D**) Quantification of CKAP2L protein expression in (**C**). Columns, mean (n=6); bars, SD. \*\**P*\<0.01, vs si-con.\
**Abbreviations:** CKAP2L, cytoskeleton-associated protein 2-like; si-con, scrambled siRNA control group.](ott-12-1171Fig2){#f2-ott-12-1171}

![Depleting CKAP2L suppresses A549 and H460 cell proliferation.\
**Notes:** (**A**) The proliferation of A549 cells determined by CCK8 assay. (**B**) The proliferation of H460 cells determined by CCK8 assay. (**C**) The proliferation of A549 cells determined by colony formation assay. (**D**) The proliferation of H460 cells determined by colony formation assay. \*\**P*\<0.01, vs si-con.\
**Abbreviations:** CCK8, cell counting kit-8; CKAP2L, cytoskeleton-associated protein 2-like; si-con, scrambled siRNA control group.](ott-12-1171Fig3){#f3-ott-12-1171}

###### 

Silencing *CKAP2L* suppressed A549 and H460 cell migration and invasion detected by Transwell assays.

**Notes:** (**A**) Depleting *CKAP2L* inhibited A549 cell migration and invasion. (**B**) Depleting *CKAP2L* inhibited H460 cell migration and invasion. 200× magnification. The bar represents 200 µm. \*\**P*\<0.01, vs si-con.

**Abbreviations:** CKAP2L, cytoskeleton-associated protein 2-like; si-con, scrambled siRNA control group.
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![Silencing *CKAP2L* suppressed A549 and H460 cell migration detected by wound healing assay.\
**Notes:** (**A**) Depleting *CKAP2L* decreased the migration distance of A549 cell. (**B**) Depleting *CKAP2L* decreased the migration distance of H460 cell. 100× magnification. The bar represents 200 µm. \*\**P*\<0.01, vs si-con.\
**Abbreviations:** CKAP2L, cytoskeleton-associated protein 2-like; si-con, scrambled siRNA control group.](ott-12-1171Fig5){#f5-ott-12-1171}

![Silencing *CKAP2L* suppressed MAPK signaling pathway.\
**Notes:** (**A**) The protein expression of p-MEK, MEK, p-ERK, and ERK in A549 cells analyzed by Western blot. (**B**) The ratios of p-MEK/MEK, p-ERK/ERK obtained by Western blot. Columns, mean (n=6); bars, SD. \*\**P*\<0.01, vs si-con.\
**Abbreviations:** CKAP2L, cytoskeleton-associated protein 2-like; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated protein kinase; p-ERK, phospho-ERK; MEK, MAPK/ERK kinase; p-MEK, phospho-MEK; si-con, scrambled siRNA control group.](ott-12-1171Fig6){#f6-ott-12-1171}

###### 

The clinical--pathological characteristics of the 52 lung adenocarcinoma patients

  Variables                 Case, n (%)
  ------------------------- -------------
  Age at diagnosis, years   
   \<60                     15 (28.8)
   ≥60                      37 (71.2)
  Gender                    
   Female                   32 (61.5)
   Male                     20 (38.5)
  Stage                     
   I + II                   29 (55.8)
   III + IV                 23 (44.2)
  T stage                   
   T1 + T2                  44 (84.6)
   T3 + T4                  8 (15.4)
  Lymph node status         
   N0                       29 (55.8)
   N1 + N2 + N3             23 (44.2)
  Metastasis                
   M0                       39 (75.0)
   M1                       13 (25.0)

###### 

The association between CKAP2L expression and the clinical--pathological factors of 52 lung adenocarcinoma patients

  Characteristics     Expression of CKAP2L   *P*-value   
  ------------------- ---------------------- ----------- ---------------------------------------------------
  Age, years                                             0.760
   \<60               7                      8           
   ≥60                19                     18          
  Gender                                                 0.569
   Female             17                     15          
   Male               9                      11          
  Stage                                                  0.000[\*](#tfn1-ott-12-1171){ref-type="table-fn"}
   I + II             22                     7           
   III + IV           4                      19          
  T-stage                                                0.050
   T1 + T2            25                     19          
   T3 + T4            1                      7           
  Lymph node status                                      0.002[\*](#tfn1-ott-12-1171){ref-type="table-fn"}
   N0                 20                     9           
   N1 + N2 + N3       6                      17          
  Metastasis                                             0.025[\*](#tfn1-ott-12-1171){ref-type="table-fn"}
   M0                 23                     16          
   M1                 3                      10          

**Note:**

*P*\<0.05.

**Abbreviation:** CKAP2L, cytoskeleton-associated protein 2-like.

###### 

COX proportional hazards model analysis of clinical--pathological characteristics for overall survival in 52 lung adenocarcinoma patients

  Variables                             Univariate analysis                                  Multivariate analysis                                                                               
  ------------------------------------- ---------------------------------------------------- ----------------------- --------------- --------------------------------------------------- ------- ---------------
  CKAP2L expression (high/low)          0.0298[\*](#tfn3-ott-12-1171){ref-type="table-fn"}   2.522                   1.097--5.799    0.430                                               1.429   0.589--3.465
  Stage (I + II/III + IV)               0.003[\*](#tfn3-ott-12-1171){ref-type="table-fn"}    3.527                   1.545--8.050    0.839                                               0.887   0.279--2.822
  T-Stage (T1 + T2/T3 + T4)             0.011[\*](#tfn3-ott-12-1171){ref-type="table-fn"}    3.182                   1.308--7.743    0.626                                               0.752   0.239--2.363
  Metastasis (M0/M1)                    0.005[\*](#tfn3-ott-12-1171){ref-type="table-fn"}    3.365                   1.430--7.920    0.015[\*](#tfn3-ott-12-1171){ref-type="table-fn"}   4.579   1.348--15.554
  Lymph node status (N0/N1 + N2 + N3)   0.001[\*](#tfn3-ott-12-1171){ref-type="table-fn"}    4.322                   1.791--10.427   0.003[\*](#tfn3-ott-12-1171){ref-type="table-fn"}   5.318   1.777--15.916
  Age (\<60/≥60), years                 0.439                                                1.437                   0.573--3.606                                                                
  Gender (female/male)                  0.648                                                0.826                   0.364--1.874                                                                

**Note:**

*P*\<0.05.

**Abbreviations:** CKAP2L, cytoskeleton-associated protein 2-like; HR, hazard ratio.
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